New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:14 EDTRLYPRelypsa announces commercial manufacturing agreement with DSM Fine Chemicals
Relypsa announced that it has entered into a multi-year commercial manufacturing and supply agreement with DSM Fine Chemicals Austria NFG GMBH & Co. KG for the active pharmaceutical ingredient for patiromer, the company's novel polymer in development for the treatment of hyperkalemia. DSM Fine Chemicals is a business unit of the newly formed DPx Holding B.V. which also owns Patheon Pharma Services and Banner Life Sciences. In addition to DSM Fine Chemicals, the company also has an agreement with Lanxess Corporation for the supply of API. Both Lanxess and DSM Fine Chemicals have manufactured and supplied API that was used during the company's clinical development program. Relypsa expects Lanxess will be the initial sole manufacturer named in its planned New Drug Application, or NDA. The company plans to submit a NDA supplement seeking approval for DSM Fine Chemicals as an additional manufacturer upon potential U.S. approval of patiromer.
News For RLYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
08:31 EDTRLYPRelypsa announces employment inducement grants
Relypsa announced that on October 1, 2015, the compensation committee of the company's board of directors granted four new employees options to purchase an aggregate of 5,750 shares of the company's common stock with a per share exercise price of $18.54, the closing trading price on the grant date, and 2,875 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5635c4 of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use